Evidence map›Paper›PMID 36316782›Full record

ArticleJournal of translational medicine2022

Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.

Jianmei Huang, Meiying Li, Bingjie Mei, Junyang Li, Yi Zhu, Qiaoshan Guo, Jianming Huang, Guonan Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jianmei HuangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Meiying LiBiochemistry and Molecular Biology, Sichuan Cancer Institute, Chengdu, China.
Bingjie MeiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Junyang LiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Yi ZhuDepartment of Ultrasound, Sichuan Cancer Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Qiaoshan GuoBiochemistry and Molecular Biology, Sichuan Cancer Institute, Chengdu, China.
Jianming HuangBiochemistry and Molecular Biology, Sichuan Cancer Institute, Chengdu, China. wesleyhuangcn2002@163.com.
Guonan ZhangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China. zhanggn@hotmail.com.ORCID 0000-0002-2228-9197
University of Electronic Science and Technology of China · CNSichuan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant sialoglycans on the surface of tumor cells shield potential tumor antigen epitopes, escape recognition, and suppress activation of immunocytes. α2,3/α2,6Gal- and α2,6GalNAc (Gal/GalNAc)-linked sialic acid residues of sialoglycans could affect macrophage galactose-type lectins (MGL) mediated-antigen uptake and presentation and promote sialic acid-binding immunoglobulin-like lectins (Siglecs) mediated-immunosuppression. Desialylating sialoglycans on tumor cells could present tumor antigens with Gal/GalNAc residues and overcome glyco-immune checkpoints. Thus, we explored whether vaccination with desialylated whole-cell tumor vaccines (DWCTVs) triggers anti-tumor immunity in ovarian cancer (OC).

methodsSialic acid (Sia) and Gal/GalNAc residues on OC A2780, OVCAR3, and ID8 cells treated with α2-3 neuraminidase (α2-3NA) and α2-6NA, and Sigec-9 or Siglec-E and MGL on DCs pulsed with desialylated OC cells were identified using flow cytometry (FCM); RT-qPCR determined IFNG expression of T cells, TRBV was sequenced using Sanger sequencing and cytotoxicity of αβ T cells was measured with LDH assay; Anti-tumor immunity in vivo was validated via vaccination with desialylated whole-cell ID8 vaccine (ID8 DWCTVs).

resultsGal/GalNAc but not Sia residues were significantly increased in the desialylated OC cells. α2-3NA-modified DWCTV increased MGL but decreased Siglec-9 or Siglec E expression on DCs. MGL

conclusionDesialylated tumor cell vaccine could promote anti-tumor immunity and provide a strategy for OC immunotherapy in a clinical setting.

Indexed as

Cancer VaccinesOvarian NeoplasmsAnimalsAntigensApoptosisCell Line, TumorEpitopesFemaleGalactoseHumansMiceN-Acetylneuraminic AcidSialic Acid Binding Immunoglobulin-like LectinsAntigensCancer VaccinesEpitopesGalactoseN-Acetylneuraminic AcidSialic Acid Binding Immunoglobulin-like LectinsGal/GalNAcMGLSialoglycansSiglec-9TCR-Vβ repertoireTumor vaccine

Identifiers

PMID36316782
PMCPMC9620617
OpenAlexW4307886216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.